Dubrovnik Conference on Cancer Mechanisms and Drug Discovery

05-09 September, 2025

Hotel Croatia, Cavtat

Organizers

Ruth Palmer, Janos Terzic, Pier Paolo DiFiore, Ivan Dikic, Geert Kops, Letizia Lanzetti, Krishnaraj Rajalingam and Wee Wei Tee

Friday Sep 5, 2025

12-16.00 Arrival and registration	
Session I Oncogenic Signalling networks	
Chairs: Ruth Palmer and Janos Terzic	
16.00-16.10 Welcome and introduction	
16.10-16.40 Keynote Lecture: Joseph Schlessinger, Yale University, USA	
"Developing kinase modulators for cancer therapeutics"	
16.45-17:15 Keynote Lecture: Tony Hunter, SALK Institute, USA	
"A journey from phosphotyrosine to phosphohistidine and beyo	ond"
17.20-17.40 Letizia Lanzetti, Torino University, Italy	
"Oncogenic trafficking"	
17.45-18.05 EMBO Global Investigator Lecture: Wee Wei Tee, IMCB, Singa	-
"Targeting transcriptional dysregulation in cancer: Insights fro development"	om early
18.10-18.30 Pier Paolo DiFiore, EIO, Italy	
"Stemness in cancer"	

Saturday Sep 6, 2025

Session II	Tumor Rewiring
	Chairs: Ivan Dikic and Letizia Lanzetti
09.00-09.20	Serkan Kir, Koç University, Turkey "EDA2R signaling in tumor-induced muscle wasting"
09.25-09.45	Sara Sigismund, IEO, Milan, Italy "Endocytic control of cell plasticity in cancer"
09.50-10.10	Volker Dötsch, Goethe University Frankfurt, Germany "Rewiring the p53 family in cancer"
10.15-10.35	Ruth Palmer, University of Gothenburg, Sweden "The ALK-dependant metabolic landscape in neuroblastoma"
10.40 -11.10	Tea Break
11.10-11.30	René Bernards, NKI, Netherlands "Combination therapies targeting RAS mutant tumors"
11.35-11.55	Mallika Singh, Revolution Medicine, USA "Targeting Ras"
12.00-12.20	Krishna Rajalingam, Mainz University, Germany "Targeting MYC and RAS -the two co-conspirators in cancer with flavagline derivatives"
12.25-12.37	Selected talk: Markus Diefenbacher, Helmholtz Center Munich, Germany "Targeting Ubiquitin Signaling vulnerabilities in KEAP1-Inactivated Lung Cancer"
12.40-13.00	Flash talks (15)
13.00-13.20	Industry/Sponsor Talk - WuXi AppTec
13.00-15.30	Lunch break and free time
Session III	Oncogenic Signaling and Genome Instability
	Chairs: Wee Wei Tee and Marta Miaczynska
15.30-15.50	Ofer Shoshani, Weizmann, Israel "Mechanisms and consequences of chromosome catastrophes in cancer"
15.55-16.15	Iva Tolić, RUĐER BOŠKOVIĆ Institute, Croatia "Mechanobiology of mitosis and its role in mitotic fidelity"

16.20-16.40	Samuel Bakhoum, Geisel School of Medicine at Dartmouth, USA "How chromosomal instability drives tumor progression"
16.45-17.05	Rene Medema, Princess Maxima Center, Netherlands "Adaptation to genome instability"
17.10-17.40	Break
17.40-18.00	Ivan Dikic, Goethe University Frankfurt, Germany "DNA-protein crosslinks,chromosome instability and liver cancer"
18.05-18.25	Geert Kops, Hubrecht Institute, Netherlands "Chromosome segregation"
18.30-18.42	Selected talk: Stamatis Papathanasiou, Mainz University, Germany "Mitotic errors as a source of inherited (epi)genetic instability"
18.45-18.55	EMBO Global Investigator Lecture: Dennis Kappei, CSI, Singapore "Give me a break – how telomere-driven genomic instability contributes to carcinogenesis"

Free for dinner and discussion

Sunday Sep 7, 2025

	Callular Diacticity in Cancar
	Cellular Plasticity in Cancer
(Chairs: Krishnaraj Rajalingam and Johanna Ivaska
09.00-09.20 I	Maria Sibilia, Medical University of Vienna, Austria
,	"Microenvironmental drivers of inflammation and tumorigenesis: Modulating
	innate immune cell signaling to enhance anti-cancer therapy"
	Marta Miaczynska, IIMCB Warsaw, Poland
"	"Targeting AXL-dependent Trafficking and Signaling in Oncogenesis"
09.50-10.02	Selected talk: Sourav Banerjee, University of Dundee, UK
•	"An atypical, secreted kinase promotes the 'seed and soil' of high-grade brain
C	cancer"
10.05-10.17	Selected talk: Iván Plaza-Menacho, CNIO, Madrid, Spain
	"The oncogenic CCDC6-RET fusion product is a dual ATP and ADP-dependent
	kinase that functions via cis-autophosphorylation"
r	kindse that functions via als autophospholylation
10.20-10.50	Tea Break
10.50-11.10 J	John Scott, University of Washington, USA
	"AKAP signaling and tumor metastasis"
	Roger Daly, Monash University, Australia
•	"Pseudokinases in Cancer"

11.40-11.52	Selected talk: Tiphaine Douanne, CNRS, Université de Nantes, France "The LUBAC negatively regulates mitochondrial apoptosis and associated inflammation"
11.55-12.20	Flash talks (15)
12.30-14.00	Lunch
14.00-16.00	Poster session I

16.30-23.00 Excursion to Dubrovnik and free time for dinner (bus return at 22:00 and at 23:00)

Monday Sep 8, 2025

Session V	Tumor Microenvironment and Metastasis
	Chairs: Maria Sibilia and Dennis Kappei
09.00-09.20	Anwesha Dey, Genentech, USA "Targeting the Hippo Pathway in Cancers"
09.25-09.45	Angel Lopez, SA Pathology, Australia "How cytokine receptors specify cell fate in heath and disease"
09.50-10.10	Colinda Scheele, VIB – KU Leuven, Belgium "Intravital imaging and dynamics of tumour progression"
10.15-10.27	Selected talk: Michael Trpceski, Garvan Institute, Sydney, Australia "Pinpointing and targeting novel drivers of pancreatic cancer progression and metastasis using TRAP-seq"
10.30-11.00	Tea Break
11.00-11.20	Daniela Krause, Mainz University, Germany "Targeting bone marrow microenvironment in leukemia"
11.25-11.45	Janos Terzic, University of Split, Croatia "Gut microbiota carcinogen metabolism and tumor metastasis"
11.50-12.10	Johanna Ivaska, University of Turku, Finland "Tumour-stroma crosstalk mediated regulation of drug sensitivity and metastasis"
12.15-12.27	Selected talk: Anna Renzi, University of Trieste, Italy "The Prolyl Isomerase Pin1 Mediates Immune Evasion in Fibrotic Breast Cancer via Suppression of Transposable Elements"
12.30-12.45	Bernd Pulverer, EMBO Press, Germany "From Bench to Journal: Connecting Open Science and Publishing"

Session VI Therapy sensitivity and resistance Chairs: Mallika Singh and Pier Paolo DiFiore Mike Yaffe, MIT Center for Precision Cancer Medicine, USA 17.00-17.20 "CRISPR-Based Screening Reveals Mechanisms of Chemotherapy Sensitization and Resistance in Glioblastoma and Ovarian Cancer" 17.25-17.45 Stuart Pitson, University of South Australia, Australia "Therapy resistance mechanisms in myeloid cancers" Selected talk: Matheus Henrique Dias, Princes Maxima Centrum, NL 17.50-18.02 "Therapeutic OVERactivation of oncogenic signaling as a cancer treatment strategy" 18.05-18.17 Selected talk: Nenad Pavin, University of Zagreb, Croatia "Macro-karyotype approach reveals a universal selection principle across cancer types" 20.00 **Farewell dinner**

Tuesday Sep 9, 2025

Session VII	Emerging therapeutics and diagnostics
	Chairs: Rene Medema and Daniela Krause
09.30-09.50	Madelon Maurice, UMC Utrecht & Oncode Institute, NL
	"SureTACs: targeting membrane protein degradation in cancer"
09.55-10.15	Paul Timpson, Garvan Institute, Australia
	"Intravital imaging of pancreatic cancer response using live biosensors imaging"
10.20-10:40	Jennie Lill, Genentech, USA
	"Proteomics in drug discovery, development and clinical monitoring in Oncology"
10.45-10:57	Selected talk: Tanmoy Mondal, University of Gothenburg, Sweden
	"Epitranscriptomic Modifications in Neuroblastoma: A Promising New
	Therapeutic Target"
11.00-11.30	Tea Break

11.30-11.50 **Connie Jimenez, UMC-Cancer Center, Netherlands**"Phosphoproteomics for target discovery and treatment response prediction in cancer"

11.55-12:07 Selected talk: Beatrice Tosoni, University of Padua, Italy "QN-302: a novel G-quadruplex-binding molecule shows high efficacy against liposarcoma"

12.10-12.30 **Anguraj Sadanandam, ICR, UK**"Immune, Stromal and Metabolic Heterogeneity in Pancreatic Cancer and its Impact on Therapeutic Responses"

12.30-13.00 Closing ceremony, poster awards and final remarks

Lunch and Departure